Shidong Xu

Changsha, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.

Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 11, 2026

Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: June 24, 2026

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.

Journal: Nature communications

Published: September 13, 2025

Baseline expression of c-Myc defines the tissue specificity of oncogenic K-Ras.

Baseline expression of c-Myc defines the tissue specificity of oncogenic K-Ras.

Journal: bioRxiv : the preprint server for biology

Published: August 08, 2025

Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: July 22, 2025

Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer.

Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer.

Journal: Cancer

Published: July 18, 2025

Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.

Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 30, 2025

A translational study on the survival and molecular mechanism of PD-L1 expression in EGFR-mutant NSCLC treated with osimertinib.

A translational study on the survival and molecular mechanism of PD-L1 expression in EGFR-mutant NSCLC treated with osimertinib.

Journal: iScience

Published: June 11, 2025

Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer.

Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 25, 2025

Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges.

Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges.

Journal: Cancer medicine

Published: March 22, 2025

NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer.

NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 10, 2025

Showing 1-11 of 11

Last Updated: 09/26/2026